GLP-1 Medications and Insulin Resistance: What the Research Shows

Introduction

Insulin resistance sits at the center of nearly every major metabolic disease — type 2 diabetes, non-alcoholic fatty liver disease, polycystic ovary syndrome, and cardiovascular disease all share insulin resistance as a driving mechanism. Yet for decades, the pharmacological tools to address it directly were limited.

GLP-1 receptor agonists changed that equation. Clinical trials show that semaglutide and tirzepatide do not simply lower blood sugar — they actively improve how the body responds to insulin across multiple tissues simultaneously.

Evidence: "Once-weekly semaglutide led to a mean weight loss of 14.9% over 68 weeks in adults with obesity, accompanied by significant improvements in fasting insulin and insulin sensitivity markers." — Wilding JPH, et al. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2032183

This article reviews the mechanisms behind GLP-1's insulin-sensitizing effects and the clinical evidence supporting its use as a targeted treatment for insulin resistance.

What Is Insulin Resistance?

Insulin resistance occurs when cells in the liver, skeletal muscle, and adipose tissue fail to respond normally to insulin signals. The pancreas compensates by secreting more insulin, leading to hyperinsulinemia — which is itself toxic over time, accelerating cardiovascular damage, worsening fat storage, and suppressing fat oxidation.

The condition exists on a spectrum. Mild insulin resistance may go undetected for years; severe resistance progresses to beta-cell exhaustion and frank type 2 diabetes. The standard clinical proxy is the HOMA-IR score (Homeostatic Model Assessment of Insulin Resistance), calculated from fasting glucose and fasting insulin. Values above 2.5–3.0 generally indicate clinically meaningful insulin resistance.

Lifestyle interventions — dietary change and exercise — can improve HOMA-IR substantially, but adherence is difficult and the underlying hormonal drivers often persist. This is where GLP-1 medications offer a pharmacological advantage.

How GLP-1 Medications Combat Insulin Resistance

GLP-1 receptor agonists do not work through a single pathway. They improve insulin sensitivity across at least three distinct organ systems, each through separate mechanisms.

Hepatic Insulin Sensitization

The liver is the primary site of fasting glucose production via gluconeogenesis and glycogenolysis. In insulin-resistant individuals, the liver continues producing glucose even when insulin is high — a phenomenon called hepatic insulin resistance.

GLP-1 receptor activation reduces hepatic glucose output through several routes: it suppresses glucagon (which normally stimulates gluconeogenesis), reduces hepatic fat content, downregulates inflammatory signaling in hepatic tissue, and decreases enterocyte chylomicron production, which limits hepatic lipid loading. The result is a liver that responds more appropriately to insulin's signal to stop producing glucose.

Skeletal Muscle Glucose Uptake

Skeletal muscle accounts for roughly 80% of post-meal glucose disposal, making it the dominant site of peripheral insulin resistance. GLP-1 receptor agonists improve muscle glucose uptake through both direct and indirect mechanisms.

Directly, GLP-1 signaling activates AMPK pathways in muscle cells, increasing GLUT4 transporter expression and promoting glycogen synthesis. Indirectly, by increasing microvascular recruitment in skeletal muscle, GLP-1 enhances local insulin delivery to muscle fibers — effectively amplifying the concentration of insulin reaching muscle cells.

Evidence: "GLP-1 receptor agonists increase insulin sensitivity in skeletal muscle through AMPK activation, which increases GLUT4 gene expression and glycogen synthesis, as well as improving microvascular insulin delivery." — Spotlight on the Mechanism of Action of Semaglutide. PMC. PubMed

Adipose Tissue Remodeling

Visceral adipose tissue in insulin-resistant individuals secretes pro-inflammatory adipokines — including TNF-α, IL-6, and resistin — that directly impair insulin signaling in distant tissues. GLP-1 receptor agonists reduce visceral fat mass, decrease adipokine secretion, and reduce ER stress within adipocytes, leading to improved adipocyte function and reduced systemic inflammation.

This anti-inflammatory action in adipose tissue creates a positive feedback loop: as inflammation decreases, peripheral insulin sensitivity improves further, independent of weight loss per se.

Clinical Evidence: Key Trials

STEP 1 — Semaglutide 2.4 mg in Obesity

The landmark STEP 1 trial randomized 1,961 adults with obesity (without diabetes) to once-weekly semaglutide 2.4 mg or placebo for 68 weeks. Beyond the well-publicized 14.9% mean weight loss, participants showed significant reductions in fasting insulin, HOMA-IR, and waist circumference — all markers of improved insulin sensitivity.

The magnitude of metabolic improvement tracked closely with weight loss, but even after adjusting for weight change, semaglutide treated participants showed greater glycemic improvements than would be predicted by weight loss alone, suggesting direct insulin-sensitizing effects.

Evidence: "Semaglutide 2.4 mg once weekly resulted in mean weight loss of 14.9% versus 2.4% with placebo, with substantial improvements in cardiometabolic risk factors including insulin sensitivity markers." — Wilding JPH, et al. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2032183

SURPASS-2 — Tirzepatide vs. Semaglutide in Type 2 Diabetes

The SURPASS-2 trial directly compared tirzepatide (5 mg, 10 mg, and 15 mg weekly) against semaglutide 1 mg in 1,879 adults with type 2 diabetes over 40 weeks. All three tirzepatide doses significantly outperformed semaglutide on HbA1c reduction, weight loss, and fasting glucose — outcomes closely tied to insulin sensitivity.

Evidence: "Tirzepatide at all doses resulted in superior reductions in HbA1c and body weight compared to semaglutide 1 mg, with mean HbA1c reductions of 2.01–2.30% versus 1.86% for semaglutide." — Frías JP, et al. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2107519

Phase 1 Clamp Study — Tirzepatide's Direct Effects on Insulin Sensitivity

A Phase 1 double-blind randomized trial directly measured insulin sensitivity using gold-standard hyperinsulinemic euglycemic clamps in adults with type 2 diabetes treated with tirzepatide, semaglutide, or placebo. This method eliminates confounding from weight loss or dietary changes.

Both active drugs improved insulin sensitivity, but tirzepatide produced significantly greater improvements — a finding attributed to its dual GIP/GLP-1 receptor agonism and the additional insulin-sensitizing properties of GIP receptor activation in adipose tissue.

Evidence: "Tirzepatide 15 mg significantly improved beta-cell function and insulin sensitivity versus both placebo and semaglutide 1 mg at 28 weeks, measured by hyperinsulinemic euglycemic clamp." — Frías JP, et al. Lancet Diabetes Endocrinol. 2022. PubMed: 35468322

Tirzepatide vs. Semaglutide: Insulin Sensitivity Beyond Weight Loss

Perhaps the most clinically significant finding in this space comes from a 2025 exploratory analysis published in Diabetes, Obesity and Metabolism. Researchers re-analyzed data from the Phase 1 clamp study, specifically asking whether tirzepatide's superior insulin sensitivity gains could be explained entirely by its greater weight loss — or whether weight-independent effects were at play.

The answer was clear: tirzepatide produced greater improvements in insulin sensitivity per unit of weight lost compared to semaglutide (p < 0.001). The correlation between weight loss and insulin sensitivity was strong for tirzepatide (R = −0.656, p < 0.0001) but much weaker for semaglutide (R = −0.268, p = 0.08), suggesting that tirzepatide's dual receptor mechanism delivers insulin-sensitizing benefits that go beyond adiposity reduction.

Evidence: "Tirzepatide was associated with greater improvement in insulin sensitivity per unit weight loss than semaglutide, not attributable to greater weight or fat loss — likely reflecting direct insulin sensitization through GIP receptor agonism in adipose tissue." — Mather KJ, et al. Diabetes Obes Metab. 2025. DOI: 10.1111/dom.16159

This distinction matters clinically. For patients whose primary concern is insulin resistance — even without severe obesity — tirzepatide may offer meaningful benefits that semaglutide does not fully replicate.

Why GIP Receptor Agonism Adds Insulin-Sensitizing Power

Tirzepatide's GIP component is not redundant. GIP receptors are densely expressed in adipose tissue, and GIP receptor activation promotes fatty acid uptake and storage in adipocytes, reducing the overflow of free fatty acids into the liver and skeletal muscle — a key driver of insulin resistance in both tissues.

This adipose "buffering" effect of GIP, combined with GLP-1's direct hepatic and muscular actions, creates a more comprehensive multi-tissue correction of insulin resistance than GLP-1 agonism alone can achieve.

Practical Implications: Who Benefits Most?

Patient Profile	Expected Benefit	Preferred Agent
Obesity with prediabetes (high HOMA-IR)	High — weight loss + direct IR improvement	Tirzepatide or semaglutide 2.4 mg
Type 2 diabetes with poor glycemic control	High — improved glucose disposal, HbA1c reduction	Tirzepatide preferred for greater IR benefit
NAFLD/MASLD with insulin resistance	High — hepatic insulin sensitization, liver fat reduction	Either; tirzepatide shows stronger hepatic benefit
PCOS with hyperinsulinemia	Moderate–high — ovarian androgen production linked to insulin	Semaglutide or tirzepatide; evidence emerging
Normal weight with isolated insulin resistance	Emerging data — direct effects independent of weight loss	Tirzepatide; weight-neutral IR benefit being studied

For patients with type 2 diabetes or prediabetes, improvements in insulin sensitivity translate directly to lower HbA1c, reduced medication burden, and protection against progressive beta-cell exhaustion. For non-diabetic obese patients, improved insulin sensitivity reduces long-term cardiovascular and cancer risk — benefits that persist even during periods of weight plateau.

For more on how these medications compare overall, see Tirzepatide vs Semaglutide: Which Is More Effective for Weight Loss? and How GLP-1 Medications Work.

Key Takeaways

GLP-1 receptor agonists improve insulin resistance through three parallel mechanisms: hepatic glucose suppression, skeletal muscle GLUT4 upregulation, and anti-inflammatory remodeling of visceral adipose tissue.
Clinical trials using gold-standard hyperinsulinemic euglycemic clamps confirm that both semaglutide and tirzepatide directly improve insulin sensitivity, not solely through weight loss.
Tirzepatide produces greater insulin sensitivity improvements per unit of weight lost than semaglutide, attributed to its additional GIP receptor agonism in adipose tissue.
Patients with the highest HOMA-IR at baseline — insulin-resistant diabetics, prediabetics, and those with NAFLD — tend to show the greatest metabolic benefit from GLP-1 treatment.
The insulin-sensitizing effects of these medications are clinically meaningful independent of their weight loss effects, broadening the rationale for their use beyond simple obesity pharmacotherapy.

References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. DOI: 10.1056/NEJMoa2107519
Frías JP, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418-429. PubMed: 35468322
Mather KJ, et al. Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis. Diabetes Obes Metab. 2025. DOI: 10.1111/dom.16159 PubMed: 39762971
Nauck MA, et al. Spotlight on the Mechanism of Action of Semaglutide. Front Endocrinol (Lausanne). 2024. PMC: 11674233
Szymańska M, et al. Impact of Selected GLP-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism — A Narrative Review. Int J Mol Sci. 2024. PMC: 11311305

Last updated: 2026-04-19 Medical review: Dr. James Chen, MD, PhD, FACE